Company intelligence / Profile preview

BioZone Pharmaceuticals

Pittsburg, California, United States

Ownership: Private
Development stage: Other

Overview

BioZone developed proprietary drug delivery technologies (QuSomes®) that improve solubility, stability, and absorption for both generic and branded drug products, particularly in dermatology and anesthesia. It successfully commercialized OTC and physician-marketed dermatology products and licensed its technology to larger pharma (e.g., OPKO) for advanced applications, but did not advance its own pipeline into later-phase clinical trials before acquisition

Therapeutic areas: NeurologyDermatologyInfectious DiseasesMetabolic DisordersOncology
Modalities: Small moleculeDrug delivery technology (QuSomes®: nanotechnology-based delivery for dermatological and pharmaceutical products)
Industry: Biotech

Partnerships

OPKO Health (licensed QuSomes for ophthalmology and other indications)Aero Pharmaceuticals (product line acquisition, Baker Cummins)

Beyond the preview

Go deeper on BioZone Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioZone Pharmaceuticals.

Explore the full profile